"Anlande Health" has completed a nearly RMB 100 million Series A financing round.

36Kr has learned from Qiming Venture Partners that Anlande Health recently announced the completion of its nearly 100 million yuan Series A financing, which was exclusively invested by Qiming Venture Partners. The capital raised from this round will be mainly used to accelerate the progress of domestic registered clinical trials for the company's core product OpusOne™, and fully support the application and launch of its early-stage overseas clinical trials.